%0 Journal Article
%T Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.
%A Palacios-Ramirez R
%A Soulié M
%A Fernandez-Celis A
%A Nakamura T
%A Boujardine N
%A Bonnard B
%A Bamberg K
%A Lopez-Andres N
%A Jaisser F
%J Clin Sci (Lond)
%V 138
%N 16
%D 2024 Aug 21
%M 39092535
%F 6.876
%R 10.1042/CS20240302
%X Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular comorbidities in animal models and patients. The present study evaluates the effects of the MR modulator balcinrenone and the MRA eplerenone on kidney damage in a metabolic CKD mouse model combining nephron reduction and a 60% high-fat diet. Balcinrenone and eplerenone prevented the progression of renal damages, extracellular matrix remodeling and inflammation to a similar extent. We identified a novel mechanism linking MR activation to the renal proteoglycan deposition and inflammation via the TLR4 pathway activation. Balcinrenone and eplerenone similarly blunted this pathway activation.